search button
Open Access

Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

  • Authors:
    • Tatsuaki Iwama
    • Kazutaka Horie
    • Toshiaki Yoshikawa
    • Daisuke Nobuoka
    • Manami Shimomura
    • Yu Sawada
    • Tetsuya Nakatsura

  • View Affiliations

  • Published online on: January 23, 2013     https://doi.org/10.3892/ijo.2013.1793
  • Pages: 831-838

  • Copyright: © Iwama et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glypican-3 (GPC3) is overexpressed in human hepatocellular carcinoma (HCC) but not expressed in normal tissues except for placenta and fetal liver and therefore is an ideal target for cancer immunotherapy. In this study, we identified an H2-Kb or H2-Db restricted and murine GPC3 (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope peptide in C57BL/6 (B6) mice, which can be used in the design of preclinical studies of various therapies with GPC3-target immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides predicted to bind with H2-Kb or H2-Db were selected from the mGPC3 amino acid sequence based on the binding score as calculated by the BIMAS software. We evaluated the peptide-binding affinity and confirmed that all peptides were able to bind to H2-Kb or H2-Db by in vitro cellular binding assay. Subsequently, a mixed peptide vaccine and single peptide vaccine were given to B6 mice to evaluate immunogenic potential of the 11 selected peptides. Using the splenocytes from peptide-vaccinated mice, interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays showed that mGPC3-1127-136 (AMFKNNYPSL) peptide was the most efficient for inducing CTLs among the 11 peptides. Next, we demonstrated that the mGPC3-1 peptide-specific CTL line could recognize mGPC3-expressing cancer cells, suggesting that mGPC3-1 peptide was an endogenously presented peptide. In conclusion, we identified mGPC3-1 as an H2-Kb or H2-Db restricted, mGPC3-derived CTL epitope peptide.
View Figures
View References

Related Articles

Journal Cover

March 2013
Volume 42 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 5.2
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 11.4
  • CiteScore Rank: Q1: #40/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 1.125
  • SCImago Journal Rank (SJR): 1.105
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Iwama T, Horie K, Yoshikawa T, Nobuoka D, Shimomura M, Sawada Y and Nakatsura T: Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int J Oncol 42: 831-838, 2013
APA
Iwama, T., Horie, K., Yoshikawa, T., Nobuoka, D., Shimomura, M., Sawada, Y., & Nakatsura, T. (2013). Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. International Journal of Oncology, 42, 831-838. https://doi.org/10.3892/ijo.2013.1793
MLA
Iwama, T., Horie, K., Yoshikawa, T., Nobuoka, D., Shimomura, M., Sawada, Y., Nakatsura, T."Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide". International Journal of Oncology 42.3 (2013): 831-838.
Chicago
Iwama, T., Horie, K., Yoshikawa, T., Nobuoka, D., Shimomura, M., Sawada, Y., Nakatsura, T."Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide". International Journal of Oncology 42, no. 3 (2013): 831-838. https://doi.org/10.3892/ijo.2013.1793